Kyntra Bio adds Andrew Singer to board, Maykin Ho departs after eight years

Kyntra Bio announced on October 1, 2026 that Andrew E. Singer, MBA joined its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026.¹ At the same time, Maykin Ho, Ph.D. stepped down from the Board effective September 30, 2026 after nearly eight years of service.¹

Singer brings more than 25 years of experience spanning investment banking, corporate strategy, business development and public company leadership.¹ He is currently Founder and CEO of Fika Bio Consulting, Inc., a strategic consulting firm,¹ and previously served as Head of West Coast Biotechnology Investment Banking at Credit Suisse, a Managing Director in the Biotechnology Investment Banking Group at Wells Fargo, Executive Vice President and Chief Financial Officer of Epizyme, and spent over ten years at RBC Capital Markets in the Biotechnology Investment Banking Group.¹ The company said he will serve a term expiring 2029.¹

Regarding Ho's exit, the filing states her resignation is not the result of any disagreement with the Company or its management on any matter relating to the Company's operations, policies, or practices.¹ She had joined the Company's Board in December 2018 and served in a number of capacities during her tenure, including as a member of the Audit Committee.¹

Separately, the filing discloses that Kyntra Bio signed a revised employment protection deal for its chief executive. On September 30, 2026, the Company entered into a new Change in Control and Severance Agreement with CEO Thane Wettig, replacing a prior agreement set to expire October 2, 2026.¹ The replacement runs for a three-year term ending October 2, 2029, with no material changes to the compensation or benefits payable under the agreement.¹